Grail

GRAIL is a healthcare company focused on early cancer detection through innovative blood tests. They make money by developing and selling their flagship product, Galleri, a multi-cancer early detection test that can identify over 50 types of cancer from a single blood draw. Founded in 2016, GRAIL has made significant strides in genomics and biotechnology, leveraging advanced sequencing technology and machine learning to analyze genetic data. Acquired by Illumina in 2021, GRAIL continues to expand its research and commercial efforts to transform cancer diagnostics and improve patient outcomes.

Recent Posts by Grail

1-20 of 39